风湿性疾病达标治疗策略研究的疗效与安全性:系统综述与Meta分析
该系统综述与Meta分析检索1990年1月至2023年12月PUBMED、EMBASE和CINAHL,纳入66项研究(50项类风湿关节炎、3项银屑病关节炎、1项脊柱关节炎、12项痛风)。
要点
- 银屑病关节炎和脊柱关节炎研究有限,达标治疗显示临床和功能获益但影像学结局无优势。
核心结论
- 对于活动性类风湿关节炎患者,多项研究显示达标治疗策略可提高临床应答可能性并改善健康相关生活质量,且不增加经济成本和不良事件。
- 有限的研究显示达标治疗策略在活动性银屑病关节炎和脊柱关节炎中具有临床和功能获益。
- 达标治疗策略在痛风中也被发现可改善临床和影像学结局;其他风湿性疾病的达标治疗试验尚缺乏。
研究设计与样本
- 系统综述与Meta分析,检索PUBMED、EMBASE和CINAHL从1990年1月至2023年12月,纳入达标治疗策略临床试验或观察性研究。
- 共检索到7896项研究,66项符合纳入标准,包括类风湿关节炎50项、银屑病关节炎3项、脊柱关节炎1项、痛风12项。
- 对类风湿关节炎研究中最常用的结局进行随机效应Meta分析。
主要发现
- 在类风湿关节炎比较达标治疗与常规治疗的研究中,83.3%(20/24)显示达标治疗可获得显著更好的临床结局。
- 敏感性分析显示有预设治疗方案者的临床疗效优于无预设方案者。
- 9项研究中有5项(55.6%)显示达标治疗在影像学进展方面获益更大;2/2研究显示达标治疗更具成本效益,8/8研究显示达标治疗不增加不良事件。
关键数值与推荐
- 银屑病关节炎和脊柱关节炎研究中达标治疗在临床和功能获益方面优于常规治疗,但影像学结局无优势。
- 所有痛风研究显示达标治疗可更有效控制血尿酸水平,2项研究显示达标治疗可抑制侵蚀进展或晶体沉积。
临床怎么用
- 对于活动性类风湿关节炎患者,达标治疗策略可提高临床应答和健康相关生活质量,且不增加经济成本与不良事件。
- 在活动性银屑病关节炎和脊柱关节炎中,有限研究显示达标治疗具有临床和功能获益。
- 在痛风中,达标治疗可更有效控制血尿酸水平并改善临床和影像学结局。
- 其他风湿性疾病的达标治疗试验尚缺乏。
局限性
- 其他风湿性疾病的达标治疗试验尚缺乏。
- 有限的研究显示达标治疗在活动性银屑病关节炎和脊柱关节炎中的临床和功能获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The concept of treat-to-target (T2T), a treatment strategy in which treatment is directed to reach and maintain a defined goal such as remission or low disease activity (LDA), has been explored for several diseases including rheumatic diseases such as rheumatoid arthritis (RA). However, a comprehensive review of T2T in all rheumatic diseases has not recently been undertaken. OBJECTIVE: To perform a systematic review and meta-analysis of the efficacy and safety of a T2T strategy in the management of adult patients with inflammatory rheumatic diseases. METHODS: PUBMED, EMBASE and CINAHL were searched from January 1990 to December 2023 using key words related to a T2T strategy and rheumatic diseases; T2T strategy clinical trials or observational studies were included. Clinical, physical function and radiologic outcomes, cost-effectiveness, and adverse events (AEs) of the T2T strategies were investigated and a random-effect meta-analysis was conducted for the most commonly used outcomes in RA studies. RESULTS: The search identified 7896 studies, of which 66 fit inclusion criteria, including 50 in RA, 3 in psoriatic arthritis (PsA), 1 in spondyloarthritis (SpA) and 12 in gout. For the studies comparing a T2T strategy with usual care (UC) in RA, 83.3% (20/24) showed a T2T strategy could achieve significantly better clinical outcomes, and the meta-analysis showed that patients treated with a T2T strategy were more likely to be in remission (pooled RR: 1.68 (1.47-1.92), p<0.001] and achieve DAS-28 response (pooled standardised mean difference (SMD): 0.47 (0.26-0.69), P<0.001] at 1 year than patients treated with UC. Sensitivity analyses showed that a T2T strategy with a predefined treatment protocol had better clinical efficacy than that without protocol. In terms of improving physical function and health-related quality of life (HRQoL), 11/19 (57.9%) studies found a T2T strategy was significantly more likely to achieve these than UC, with the meta-analysis for the mean change of HAQ score supporting this conclusion (pooled SMD: 1.48 (0.46-2.51), p=0.004). Five out of 9 studies (55.6%) demonstrated greater benefit regarding radiographic progression from a T2T strategy. In terms of cost-effectiveness and AEs, 2/2 studies found a T2T strategy was more cost-effective than UC and 8/8 studies showed no tendency for AEs to occur more often with a T2T strategy. For the studies in PsA and SpA, a T2T strategy was also demonstrated to be more effective than UC in clinical and functional benefits, but not in radiologic outcomes. All gout studies showed that sUA level could be controlled more effectively with a T2T strategy, and 2 studies revealed that the T2T strategy could inhibit erosion development or crystal deposition. CONCLUSIONS: For patients with active RA, a T2T strategy has been shown in mulitple studies to increase the likelihood of achieving clinical response and improving HRQoL without increasing economic costs and AEs. Limited studies have shown clinical and functional benefits from T2T strategies in active PsA and SpA. A T2T strategy has also been found to improve clinical and radiologic outcomes in gout. T2T trials in other rheumatic diseases are lacking.
引用
- Hao Y, Oon S, Nikpour M, et al. Efficacy and safety of treat-to-target strategy studies in rheumatic diseases: A systematic review and meta-analysis. Semin Arthritis Rheum. 2024. PMID: 38796922. doi:10.1016/j.semarthrit.2024.152465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。